Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series

Huber, Alexandre; Seidler, Stéphanie; Huber, Daniela

doi:10.5152/ejbh.2020.5297

Cited by 9 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past 13 years, among patients with breast cancer undergoing surgical treatment at the First Medical Center of Chinese PLA General Hospital, 98 were patients with SBBC, and 25 were patients with MBBC, accounting for 1.6% and 0.4% of the breast cancer population, respectively. The incidence of SBBC in this study was significantly higher than that of MBBC, while some studies from Western countries found that the incidence of MBBC was higher than that of SBBC ( 2 , 7 , 17 - 19 ). Some studies have also reported similar incidences of MBBC and SBBC ( 4 , 20 - 22 ).…”

Section: Discussioncontrasting

confidence: 77%

“…Based on a large population of Surveillance, Epidemiology, and Ends Results (SEER) data, Qiu et al ( 6 ) also showed an interval of 45.62 months. Recently, a study on a Western population reported that the median time interval in patients with MBBC was as long as 111 months ( 7 ). This interval is clearly longer than the time interval of MBBC in China.…”

Section: Discussionmentioning

confidence: 99%

“…A meta-analysis showed that the incidence of SBBC and MBBC in patients with breast cancer was 2% [95% confidence interval (CI): 2-3%] and 3% (95% CI: 2-5%), respectively (2). The time interval to distinguish between SBBC and MBBC is still controversial, ranging from 3 months to 5 years (3)(4)(5)(6)(7). The World Health Organization (WHO) defined the threshold as 3 months (8).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological features and prognosis of bilateral breast cancer: a single-center cohort study based on Chinese data

et al. 2022

View full text Add to dashboard Cite

Background The incidence of bilateral breast cancer (BBC) is low, accounting for 5% of patients with breast cancer. This study aimed to investigate the clinicopathological features and prognosis of synchronous bilateral breast cancer (SBBC) and metachronous bilateral breast cancer (MBBC) in the Chinese population. Methods Patients with BBC, including SBBC and MBBC, were selected from 6,162 breast cancer patients who underwent surgery at the Chinese People’s Liberation Army (PLA) General Hospital between January 2007 and December 2019. Furthermore, patients with unilateral breast cancer (UBC) who underwent surgery at the same time were randomly selected at a ratio of 1:2 as the control group. Clinicopathological features and prognosis were compared between the groups. Results In all, 123 (2.0%) patients with BBC were enrolled in this study, including 98 (1.6%) SBBC and 25 (0.4%) MBBC patients. A total of 280 patients with UBC were selected for the control group. Compared with patients with UBC, patients with SBBC were more likely to be older and have a family history of breast cancer, non-infiltrative carcinoma, lower pathological tumor-node-metastasis (pTNM) stage, and luminal A type breast cancer as their first tumor. Patients with MBBC were more likely to be postmenopausal and have hormone receptor [estrogen receptor (ER)/progesterone receptor (PR)] negativity, a higher pTNM stage, and a triple-negative first tumor. Patients with UBC with ER/PR (−) were more likely to develop contralateral breast cancer (CBC) than those with ER/PR (+). There was no significant difference in overall survival (OS) and disease-free survival (DFS) between patients with SBBC and patients with UBC. Patients with MBBC had worse DFS than those with UBC, but OS was similar for both types of patients. Patients with MBBC <55 years at first diagnosis had significantly shorter DFS compared to those with SBBC and UBC. A multivariate Cox proportional hazards model revealed that age ≥55 years and ER/PR negativity of the first tumor were independent risk factors for OS. Independent risk factors for DFS included MBBC, age <55 years, family history of other malignant tumors, ER/PR (−), lymphovascular invasion, and N stage ≥2 of the first tumor. Conclusions The OS and DFS of patients with SBBC and UBC were similar. The MBBC patients, especially those <55 years old at first diagnosis, had shorter DFS than patients with UBC.

show abstract

Section: Discussioncontrasting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological features and prognosis of bilateral breast cancer: a single-center cohort study based on Chinese data

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The incidence of BBC is slightly higher, 3%, than all BCs. More precisely, synchronous tumors (contemporary bilaterality) represent 0.6%, while those metachronous constitute 2.2% [32,33].…”

Section: Discussionmentioning

confidence: 99%

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

Fanale

Incorvaia

Filorizzo

et al. 2020

Cancers

View full text Add to dashboard Cite

Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast cancer (BBC). The annual risk of contralateral BC is about 0.5%, but increases by up to 3% in BRCA1 or BRCA2 pathogenic variant (PV) carriers. Our study was aimed to evaluate whether all BBC patients should be offered multi-gene panel testing, regardless their cancer family history and age at diagnosis. We retrospectively collected all clinical information of 139 BBC patients genetically tested for germline PVs in different cancer susceptibility genes by NGS-based multi-gene panel testing. Our investigation revealed that 52 (37.4%) out of 139 BBC patients harbored germline PVs in high- and intermediate-penetrance breast cancer (BC) susceptibility genes including BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, RAD51C. Nineteen out of 53 positively tested patients harbored a PV in a known BC susceptibility gene (no-BRCA). Interestingly, in the absence of an analysis performed via multi-gene panel, a significant proportion (14.4%) of PVs would have been lost. Therefore, offering a NGS-based multi-gene panel testing to all BBC patients may significantly increase the detection rates of germline PVs in other cancer susceptibility genes beyond BRCA1/2, avoiding underestimation of the number of individuals affected by a hereditary tumor syndrome.

show abstract

“…6 Previous studies have reported inconsistent results regarding the prognosis of sBBC and mBBC. Some studies have reported similar outcomes between sBBC and mBBC, 15,18,49 but other studies have reported a poorer survival of patients with mBBC than those with sBBC. 25,39 This study has several limitations.…”

Section: Discussionmentioning

confidence: 99%

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)

et al. 2021

View full text Add to dashboard Cite

Breast cancer (BC) is the most commonly diagnosed cancer and the leading cause of cancer-related deaths among women worldwide. 1 In China, BC is the most common tumor in women, and it was the fifth most common cancer causing cancer-related deaths in 2015. 2 Bilateral breast cancer (BBC), defined as the presence of primary cancer in each breast, is an uncommon subset of BC. The incidence of BBC has increased in recent years,

show abstract

Clinicopathological Characteristics, Treatment and Outcome of 123 Patients with Synchronous or Metachronous Bilateral Breast Cancer in a Swiss Institutional Retrospective Series

Cited by 9 publications

References 28 publications

Clinicopathological features and prognosis of bilateral breast cancer: a single-center cohort study based on Chinese data

Clinicopathological features and prognosis of bilateral breast cancer: a single-center cohort study based on Chinese data

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)

Contact Info

Product

Resources

About